Sonoma Pharmaceuticals, Inc. (NASDAQ: SPHB) reported that its Controller, John Dal Poggetto, was granted 7,500 Restricted Stock Units (RSUs) on July 1, 2024. According to the company’s Form 4 filing with the U.S. Securities and Exchange Commission (SEC), these units represent a contingent right to receive shares of common stock, subject to specific vesting requirements.
Details of the Equity Grant
The grant of 7,500 RSUs serves as a form of equity compensation for the company’s executive leadership. As disclosed in the official SEC filing, these units are not immediately tradable. Instead, the vesting schedule dictates that the shares will be released to the recipient over time, provided that the individual remains employed by the company.
This transaction is part of the standard equity incentive programs often utilized by biotechnology firms to align the interests of management with those of shareholders. By providing equity-based compensation, Sonoma Pharmaceuticals incentivizes long-term performance and retention among its key financial officers.
Understanding Restricted Stock Units (RSUs)
RSUs function differently than traditional stock options. While an option gives an employee the right to purchase stock at a set price, an RSU is a promise to deliver shares once certain conditions—typically time-based vesting—are met.
Once the vesting period expires, the units convert into actual shares of Sonoma Pharmaceuticals common stock. At that point, the recipient typically incurs a tax obligation based on the fair market value of the shares at the time of delivery. Because these instruments are tied to the company’s stock price, the ultimate value realized by the recipient depends on the market performance of Sonoma Pharmaceuticals at the time of vesting.
Sonoma Pharmaceuticals Corporate Governance
John Dal Poggetto serves as the Controller for Sonoma Pharmaceuticals, a position responsible for overseeing the company’s financial reporting, internal controls, and accounting operations. Regulatory filings such as the Form 4 are mandatory under SEC regulations, which require "insiders"—including directors, officers, and beneficial owners—to report changes in their ownership of company securities.
This transparency allows investors to monitor the equity stakes held by company management. The reporting of this grant follows standard corporate governance protocols for publicly traded entities listed on the Nasdaq exchange.
Summary of Financial Disclosure
- Company: Sonoma Pharmaceuticals, Inc. (NASDAQ: SPHB)
- Reporting Individual: John Dal Poggetto, Controller
- Transaction Date: July 1, 2024
- Security Type: Restricted Stock Units (RSUs)
- Amount Granted: 7,500 units
Investors can access the full details of this transaction via the SEC’s EDGAR database, which maintains public records of all insider trading activity for U.S.-listed corporations.